{
    "root": "2cd5dbfd-2432-4cea-bee2-6b710b5d28a2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Letrozole"
    },
    "value": "20250328",
    "ingredients": [
        {
            "name": "LETROZOLE",
            "code": "7LKK855W8I"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "letrozole aromatase inhibitor indicated : adjuvant treatment postmenopausal women hormone receptor positive early breast cancer . ( 1.1 ) extended adjuvant treatment postmenopausal women early breast cancer received prior standard adjuvant tamoxifen therapy . ( 1.2 ) first second-line treatment postmenopausal women hormone receptor positive unknown advanced breast cancer . ( 1.3 )",
    "contraindications": "letrozole tablets taken orally without regard meals ( 2 ) : recommended dose : 2.5 mg daily . ( 2.1 ) patients cirrhosis severe hepatic impairment : 2.5 mg every day . ( 2.5 , 5.3 )",
    "warningsAndPrecautions": "letrozole tablets usp 2.5 mg dark yellow , film-coated , round , slightly biconvex , beveled edges debossed \u2018 l2.5 \u2019 one side plain side . supplied follows : bottles 30 ndc 59651-180-30 bottles 90 ndc 59651-180-90 store 20o 25oc ( 68o 77of ) [ usp controlled room temperature ] .",
    "adverseReactions": "pregnancy : letrozole cause fetal harm [ ( 8.1 ) ] . known hypersensitivity active substance , excipients [ ( 6 ) ] .",
    "indications_original": "Letrozole is an aromatase inhibitor indicated for: Adjuvant     treatment of postmenopausal women with hormone receptor positive early breast cancer.     ( 1.1 ) Extended adjuvant treatment of postmenopausal women     with early breast cancer who have received prior standard adjuvant tamoxifen therapy.     ( 1.2 ) First and second-line treatment of postmenopausal     women with hormone receptor positive or unknown advanced breast cancer. ( 1.3 )",
    "contraindications_original": "Letrozole tablets are taken orally without regard to meals ( 2 ): Recommended dose: 2.5 mg once daily. ( 2.1 ) Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day. ( 2.5 , 5.3 )",
    "warningsAndPrecautions_original": "Letrozole Tablets USP 2.5 mg are dark yellow, film-coated, round, slightly biconvex, with beveled edges debossed with \u2018L2.5\u2019 on one side and plain on other side. They are supplied as follows:\n                  \n                  Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC 59651-180-30\n                  Bottles of 90 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 59651-180-90\n                  \n                  Store at 20o to 25oC (68o to 77oF) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Pregnancy: Letrozole\u00a0can\u00a0 cause fetal harm [see Use in Specific Populations (8.1)].\n                     \n                     Known hypersensitivity to the active substance,\u00a0or to any of the excipients [see Adverse Reactions (6)]."
}